More recently, Liolios et al. described the development of a BRL that combines PSMA-617, which has been already approved for clinical use as a PSMA-targeting prostate tumor agent, with RM2, a binding peptide of GRPR. This evidence concerns the gene FOLH1 and prostate neoplasm.